

18 January 2017

February 2017 Pharmaceutical Schedule Dispatch

This document is provided to pharmacists as an early notification of the changes to be announced in the **February 2017** Update to the Pharmaceutical Schedule. Please notify PHARMAC (enquiry@pharmac.govt.nz) if you want to change or remove your contact details.

New listings

- Carbimazole (AFT Carbimazole) tab 5 mg – S29, wastage claimable (p'code 2451034)
- Metformin hydrochloride (Apotex) tab immediate-release 850 mg (p'code 2401002)
- Paroxetine (Apo-Paroxetine) tab 20 mg (p'code 2511819)
- Pharmacy services (BSF Lorstat (p'code 2514206) and BSF Sulprix (p'code 2514192)) brand switch fee – may only be claimed once per patient
- Sumatriptan (Clustran) inj 12 mg per ml, 0.5 ml prefilled pen – maximum of 10 inj per prescription (p'code 2515393)
- Terazosin (Apo-Terazosin) tab 2 mg (p'code 2265354)

Changes to restrictions, chemical names and presentations

- Amisulpride (Sulprix) tab 100 mg, 200 mg and 400 mg – Brand Switch Fee payable
- Atorvastatin (Lorstat) tab 10 mg, 20 mg, 40 mg and 80 mg – Brand Switch Fee payable
- Human papillomavirus (6, 11, 16 and 18) vaccine [HPV] (Gardasil) inj 120 mcg in 0.5 ml syringe – amended restriction
- Levonorgestrel (Jadelle) subdermal implant (2 x 75 mg rods) – Up to 3 pack available on PSO
- Metformin hydrochloride (Metformin Mylan) tab immediate-release 850 mg – Sole Supply suspended
- Metoprolol tartrate (Apo-Metoprolol) tab 50 mg and 100 mg – Brand Switch Fee removed
- Paroxetine (Apo-Paroxetine and Loxamine) tab 20 mg – amended chemical name

Increased subsidy

Chemical	Presentation	Fully subsidised brands
Codeine phosphate	Tab 15 mg, 30 mg and 60 mg	PSM

Decreased subsidy

Chemical	Presentation	Fully subsidised brands	Partially subsidised brands
Hydrocortisone	Crm 1%	DermAssist* (30 g)	Pharmacy Health (100 g)
Loratadine	Oral liq 1 mg per ml	Lorfast* (120 ml)	LoraPaed (200 ml)
Temozolomide	Cap 20 mg, 100 mg and 250 mg	Orion Temozolomide*	Temaccord
Terazosin	Tab 5 mg	Apo-Terazosin *	Arrow
Tobramycin	Inj 40 mg per ml, 2 ml vial	Tobramycin Mylan*	DBL Tobramycin

* no subsidy changes for these brands for 1 February 2017.

Do you prefer email communications?

If you have not already contacted us and would like to receive future updates by email, please provide your email address to us at enquiry@pharmac.govt.nz. Please put "email or fax preference" in the subject line.

If email is not an option for you, and you would like to continue to receive faxed communications from us, please let us know that too.